疑似2型糖尿病青年中单基因糖尿病的患病率:ProDiGY协作研究
该研究对3333例临床诊断为2型糖尿病的20岁以下多民族青年进行全外显子测序,发现2.8%(93例)携带MODY基因的致病或可能致病变异,其中89%的特定诊断会改变临床管理。MODY患者诊断年龄更小、空腹C肽更低、高血压更少、HDL胆固醇更高,但无临床指标能可靠区分两组。
要点
- 临床诊断2型糖尿病的青年中MODY患病率为2.8%。
- 89%的MODY患者诊断会改变临床管理。
- 无临床指标能可靠区分MODY与2型糖尿病。
核心结论
- 在临床诊断为2型糖尿病的青年中,通过全外显子测序发现2.8%携带MODY基因致病变异,且89%的病例诊断会改变临床管理。
研究设计与样本
- 研究评估了3333例临床诊断为2型糖尿病的20岁以下青年的全外显子测序数据,将携带MODY基因可能致病或致病变异者定义为MODY。
主要发现
- 93例(2.8%)携带HNF4A、GCK、HNF1A、PDX1、INS或CEL基因的致病变异。
- MODY组诊断年龄更小(12.9±2.5 vs. 13.6±2.3年,P=0.002)。
- MODY组空腹C肽更低(3.0±1.7 vs. 4.7±3.5 ng/mL,P<0.0001)。
- MODY组高血压更少(6.9% vs. 19.5%,P=0.007),HDL胆固醇更高(43.8 vs. 39.7 mg/dL,P=0.006)。
关键数值与推荐
- MODY基因变异按现行指南分类为可能致病或致病。
- 89%(n=83)的MODY病例特定诊断会改变临床管理。
临床怎么用
- 对临床诊断为2型糖尿病的青年,应考虑MODY可能,尤其诊断年龄小、空腹C肽低、无高血压及HDL较高者。
- 基因检测可明确MODY诊断,从而指导治疗调整和家族风险评估。
局限性
- 无临床指标能可靠区分MODY与2型糖尿病,需开发新工具选择基因检测对象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Maturity-onset diabetes of the young (MODY) is frequently misdiagnosed as type 1 or type 2 diabetes. Correct diagnosis may result in a change in clinical treatment and impacts prediction of complications and familial risk. In this study, we aimed to assess the prevalence of MODY in multiethnic youth under age 20 years with a clinical diagnosis of type 2 diabetes. RESEARCH DESIGN AND METHODS: We evaluated whole-exome sequence data of youth with a clinical diagnosis of type 2 diabetes. We considered participants to have MODY if they carried a MODY gene variant classified as likely pathogenic (LP) or pathogenic (P) according to current guidelines. RESULTS: Of 3,333 participants, 93 (2.8%) carried an LP/P variant in HNF4A (16 participants), GCK (23), HNF1A (44), PDX1 (5), INS (4), and CEL (1). Compared with those with no LP/P variants, youth with MODY had a younger age at diagnosis (12.9 ± 2.5 vs. 13.6 ± 2.3 years, P = 0.002) and lower fasting C-peptide levels (3.0 ± 1.7 vs. 4.7 ± 3.5 ng/mL, P < 0.0001). Youth with MODY were less likely to have hypertension (6.9% vs. 19.5%, P = 0.007) and had higher HDL cholesterol (43.8 vs. 39.7 mg/dL, P = 0.006). CONCLUSIONS: By comprehensively sequencing the coding regions of all MODY genes, we identified MODY in 2.8% of youth with clinically diagnosed type 2 diabetes; importantly, in 89% (n = 83) the specific diagnosis would have changed clinical management. No clinical criterion reliably separated the two groups. New tools are needed to find ideal criteria for selection of individuals for genetic testing.
引用
- Todd JN, Kleinberger JW, Zhang H, et al. Monogenic Diabetes in Youth With Presumed Type 2 Diabetes: Results From the Progress in Diabetes Genetics in Youth (ProDiGY) Collaboration. Diabetes Care. 2021. PMID: 34362814. doi:10.2337/dc21-0491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。